Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Industry Valued at $3.09 Billion by 2029 With CAGR of 5.8% | Size and Share Insights
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market from 2024 to 2025?
The market size of drugs for methicillin-resistant staphylococcus aureus (MRSA) has been experiencing consistent growth over recent years. The market is expected to expand from a size of $2.35 billion in 2024 to $2.47 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.9%. This growth during the historical period has been driven by factors such as concerns over antibiotic resistance, infections acquired in hospitals, surgical procedures, a worldwide surge in MRSA cases, and high mortality rates.
What Is the Projected Market Size of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market?
In the upcoming years, the market size for methicillin-resistant staphylococcus aureus (MRSA) drugs is anticipated to experience robust growth, reaching “$3.09 billion by 2029 at an ongoing compound annual growth rate (CAGR) of 5.8%. The forthcoming expansion can be credited to enduring issues with antibiotic resistance, advancements in diagnostics for MRSA, worldwide healthcare-associated infections, surgical preventative methods, and an increase in MRSA cases acquired in the community. Key trends expected in this forecast period involve the investigation of immunomodulators, strategic collaborations for the development of drugs, personalized treatments considering strain characteristics, emphasizing pediatric-specific formulations, and international health initiatives aimed at challenging antibiotic resistance.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10859&type=smp
Who are the Major Competitors in the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Outlook?
Major companies operating in the methicillin-resistant staphylococcus aureus (MRSA) drugs market include Basilea Pharmaceutica Ltd., Merck & Co Inc., Pfizer Inc., Theravance Biopharma Inc., Allergan plc, Cumberland Pharmaceuticals Inc., Debiopharm International S.A., AbbVie Inc., Innovation Pharmaceuticals Inc., Melinta Therapeutics Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., AmpliPhi Biosciences Corporation, AstraZeneca plc, Meiji Seika Kaisha Ltd., GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Novartis, Wockhardt, Sun Pharmaceutical Industries Ltd., Lupin Limited, Glenmark Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Astellas Pharma Inc.
What Is Fueling Growth in the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market?
The growth of the market for methicillin-resistant Staphylococcus aureus (MRSA) drugs is projected to be fuelled by escalating instances of Hospital Acquired Infections (HAIs). HAIs are infections that patients contract during their stay in a healthcare facility, particularly after being admitted for 48 hours or longer. Factors contributing to HAIs include contaminated medical tools, inadequate hand cleanliness in healthcare professionals, overutilization of antibiotics, extended hospitalizations and compromised patient immunity. MRSA drugs are effective in managing HAIs, as they specifically target and eradicate MRSA strains that exhibit resistance to conventional antibiotics, thus limiting the spread and impact of such infections in healthcare environments. For example, in 2023, the World Health Organization, a Switzerland-based Intergovernmental organization, estimated that approximately 136 million healthcare-associated antibiotic-resistant infections occur annually across the world. Consequently, the escalating prevalence of methicillin-resistant Staphylococcus aureus infections is propelling the expansion of the methicillin-resistant Staphylococcus aureus drug market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10859&type=smp
Which Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Segments Are Growing the Fastest?
The methicillin-resistant staphylococcus aureus (MRSA) drugs market covered in this report is segmented –
1) By Drug Class: Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, Lipoglycopeptide, Other Drug Classes
2) By Indication: Skin Infections, Bone and Joint Infections, Bacteremia, Animal Infections
3) By MRSA Type: Hospital-Acquired (HA-MRSA), Community-Acquired (CA-MRSA)
4) By Route of Administration: Oral Administration, Parenteral Administration
5) By End User: Hospitals and Clinics, Research and Academic Institutes, Other End-Users
Subsegments:
1) By Lipopeptides: Daptomycin
2) By Oxazolidinones: Linezolid, Tedizolid
3) By Cephalosporin: Ceftaroline
4) By Tetracycline: Minocycline, Doxycycline
5) By Folate Antagonist: Trimethoprim Or Sulfamethoxazole
6) By Lipoglycopeptide: Telavancin, Dalbavancin, Oritavancin
7) By Other Drug Classes: Vancomycin, Clindamycin, Quinupristin Or Dalfopristin
Which Industry Trends Are Shaping the Future of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market?
In the Methicillin-Resistant Staphylococcus aureus (MRSA) drug market, there’s a trending emphasis on product innovation. The leading businesses within this market are prioritizing the creation of new products to enhance their market presence and maintain their competitive edge. For instance, Endo, a biopharmaceutical company situated in the US, introduced the first-ever generic variant of Pylera— which encapsulates bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride— in March 2023. This new addition to treatment options is not only affordable for patients battling Helicobacter pylori infections, but it also works towards supporting cost-effectiveness in the healthcare sector. This ultimately ensures broader access to effective ulcer therapies, guaranteeing better condition management for a larger population of patients.
Access The Full Report Here:
Which Countries Are Leading the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market?
North America was the largest region in the global methicillin-resistant staphylococcus aureus drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methicillin-resistant staphylococcus aureus (MRSA) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10859
This Report Delivers Insight On:
1. How big is the methicillin-resistant staphylococcus aureus (mrsa) drugs market, and how is it changing globally?
2. Who are the major companies in the methicillin-resistant staphylococcus aureus (mrsa) drugs market, and how are they performing?
3. What are the key opportunities and risks in the methicillin-resistant staphylococcus aureus (mrsa) drugs market right now?
4. Which products or customer segments are growing the most in the methicillin-resistant staphylococcus aureus (mrsa) drugs market?
5. What factors are helping or slowing down the growth of the methicillin-resistant staphylococcus aureus (mrsa) drugs market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
